[ad_1]
The newcomer of TecDax was able to reduce its losses only temporarily: at 37.79 euros, a significant decline of 3.5% was recorded again. Only last Thursday, the newspaper had reached the culmination of its young historical stock at 39.49 euros. By mid-March, Siemens had launched its subsidiary on the stock market with an issue price of 28 euros – since then it has gradually increased with intermediate resets.
Analyst David Adlington of US bank JPMorgan pointed to the good performance ahead of the current figures. high rating compared to competitor Philips. While Siemens Healthineers' share has jumped by around 25% since the beginning of the fiscal year, there was only 15% of Dutch over the same period.
Stagnation of the third quarter due to negative currency effects expectations up to just above. Scott Bardo, of the Berenberg private bank, hailed the strong business development of the Siemens spinoff company
On the other hand, the decline in net profit was disappointing. He also suffered start-up costs of the Atellica diagnostic system as well as one-time expenses related to a recently concluded automation contract. In addition, the higher interest payments and taxes would have weighed here, so JPMorgan expert Adlington.
Sven Diermeier of the Independent Research House of Analysis pointed to positive annual prospects confirmed. As a result, Siemens Healthineers continues to anticipate revenue growth of 3 to 4% on a comparable basis for the year ended September 30th. The adjusted profit margin is expected to reach 17 to 18% after 16% in the last quarter – the last fiscal quarter of the company is traditionally the strongest.
On the other hand complains a dealer that the medical technology company for interest payments in the current fiscal year 20 million euros already predicts 140 to 170 million of 39; euros. This should not have anticipated the market. Siemens Healthineers is largely indebted to the US dollar.
Source link
